Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Objectives All microsomal cytochrome P450s enzymes, including those that metabolize the majority of clinically used drugs, require electron transfer through P450 oxidoreductase (POR). Mutations in human POR cause altered steroidogenesis and congenital malformations, but the clinical effects on drug metabolism are unclear. We examined the effects of POR sequence variants on two drug-metabolizing P450 enzymes, CYP1A2 and CYP2C19. Methods Our previous sequencing of the human POR gene in POR-deficient patients and in 842 normal individuals identified 35 sequence variants. We expressed these 35 POR sequence variants in bacteria, reconstituted them with the CYP enzymes in vitro, and assayed their activities with human CYP1A2 and CYP2C19. Results POR variants affected the activities of these enzymes to different extents. Disease-causing POR mutations A287P and R457H diminished catalysis by CYP1A2 and CYP2C19 to barely detectable levels. POR A503V, a polymorphism found in 28% of alleles in the normal population, had 85% of wild-type activity with CYP1A2 and 113% of wild-type activity with CYP2C19. Q153R, a disease-causing mutation that severely impaired steroidogenic activity and cytochrome c reduction, increased the activity of CYP1A2 to 144% and CYP2C19 activity to 284% of control. Conclusion The activity of individual POR mutants may vary greatly depending on the electron recipient used to assay activity. Thus, the activity of a POR mutant to support catalysis by a particular P450…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Considering all available data from previous reports [4,46,47] and multiple functional assays described in this manuscript, we suggest that rs17853284, the variant causing amino acid change P228L in POR, is a disease-causing variant, whose effect will be prominent when present together with another variant of POR on the second allele that has a severe impact on POR activities.”
From Loss of Protein Stability and Function Caused by P228L Variation in NADPH-Cytochrome P450 Reductase Linked to Lower Testosterone Levels (2022) · cites this paper as [46]
In the citing paper
“but has no measurable effect on the activities of P450c21 (306) or hepatic CYP1A2 or CYP2C19 (307), but it reduces the activities of CYP2D6 and CYP3A4 to metabolize important drugs in vitro (308, 309).”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [307]
In the citing paper
“A survey of 35 POR variants with the human hepatic enzymes CYP1A2 or CYP2C19 found substantial differences among the POR variants studied, including some (notably Q153R) that increased activity”
From Steroidogenic electron-transfer factors and their diseases (2021) · cites this paper as [81]
Citations
Cites
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Miroux, B., & Walker, J. E. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0399 · Cited by 1,959
Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., & Nebert, D. W. (2004) · Pharmacogenetics · doi:10.1097/00008571-200401000-00001 · Cited by 1,027
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Moving towards individualized medicine with pharmacogenomics
Evans, W. E., & Relling, M. V. (2004) · Nature · doi:10.1038/nature02626 · Cited by 768
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Wang, M., Roberts, D. L., Paschke, R., Shea, T. M., Masters, B. S. S., & Kim, J.-J. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8411 · Cited by 744
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review
Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadee, W. (2001) · JAMA · doi:10.1001/jama.286.18.2270 · Cited by 705
Ingelman-Sundberg, M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.007 · Cited by 676
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Self-citationNADPH P450 oxidoreductase: Structure, function, and pathology of diseases
Pandey, A. V., & Flück, C. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.010 · Cited by 279
Šrejber, M., Navrátilová, V., Paloncýová, M., Bazgier, V., Berka, K., Anzenbacher, P., & Otyepka, M. (2018) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2018.03.002 · Cited by 190
de Jonge, H., Metalidis, C., Naesens, M., Lambrechts, D., & Kuypers, D. R. J. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.77 · Cited by 145
Gomes, A. M., Winter, S., Klein, K., Turpeinen, M., Schaeffeler, E., Schwab, M., & Zanger, U. M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.7 · Cited by 125
Fukami, M., Nishimura, G., Homma, K., Nagai, T., Hanaki, K., Uematsu, A., Ishii, T., Numakura, C., Sawada, H., Nakacho, M., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2816 · Cited by 117
NADPH–cytochrome P450 oxidoreductase: Prototypic member of the diflavin reductase family
Iyanagi, T., Xia, C., & Kim, J.-J. P. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.09.002 · Cited by 117
Oneda, B., Crettol, S., Sirot, E. J., Bochud, M., Ansermot, N., & Eap, C. B. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833225e7 · Cited by 115
Agrawal, V., Choi, J. H., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833e0cb5 · Cited by 104
Self-citationRole of Protein–Protein Interactions in Cytochrome P450-Mediated Drug Metabolism and Toxicity
Kandel, S. E., & Lampe, J. N. (2014) · Chemical Research in Toxicology · doi:10.1021/tx500203s · Cited by 116
Elens, L., Hesselink, D. A., Bouamar, R., Budde, K., de Fijter, J. W., Meyer, M. D., Mourad, M., Kuypers, D. R. J., Haufroid, V., van Gelder, T., et al. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31829da6dd · Cited by 103
Shahabi, P., Siest, G., Meyer, U., & Visvikis‐Siest, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.05.011 · Cited by 107
Pharmacogenomics of human P450 oxidoreductase
Pandey, A. V., & Sproll, P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00103 · Cited by 92
“Many recent studies reported effects of POR variants on several drug metabolizing P450s (Agrawal et al., 2008, 2010; Hart et al., 2008; Kranendonk et al., 2008; Gomes et al., 2009; Miller et al., 2009; Oneda et al., 2009; Flück et al., 2010; Marohnic et al., 2010; Nicolo et al., 2010; Tomalik-Scharte et al., 2010) and…”
BackgroundInfluentialExtraadrenal 21-Hydroxylation by CYP2C19 and CYP3A4: Effect on 21-Hydroxylase Deficiency
Gomes, L. G., Huang, N., Agrawal, V., Mendonça, B. B., Bachega, T. A. S. S., & Miller, W. L. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1174 · Cited by 91
Self-citationConsequences of POR mutations and polymorphisms
Miller, W. L., Agrawal, V., Sandee, D., Tee, M. K., Huang, N., Choi, J. H., Morrissey, K., & Giacomini, K. M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.10.022 · Cited by 88
Self-citationClinical, genetic and enzymatic characterization of P450 oxidoreductase deficiency in four patients
Sahakitrungruang, T., Huang, N., Tee, M. K., Agrawal, V., Russell, W. E., Crock, P., Murphy, N., Migeon, C. J., & Miller, W. L. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1460 · Cited by 82
Self-citationP450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms
Burkhard, F. Z., Parween, S., Udhane, S. S., Flück, C. E., & Pandey, A. V. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.04.003 · Cited by 79
Tomalik-Scharte, D., Maiter, D., Kirchheiner, J., Ivison, H. E., Fuhr, U., & Arlt, W. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0764 · Cited by 77
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro
Sandee, D., Morrissey, K., Agrawal, V., Tam, H. K., Kramer, M. A., Tracy, T. S., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833f4f9b · Cited by 74
Self-citationElectron Transfer Partners of Cytochrome P450
Waskell, L. A., & Kim, J. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-12108-6_2 · Cited by 87
Flück, C. E., Mullis, P. E., & Pandey, A. V. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.09.035 · Cited by 59
Zane, N. R., Chen, Y., Wang, M. Z., & Thakker, D. R. (2017) · Pediatric Research · doi:10.1038/pr.2017.226 · Cited by 57
Genetic variation in human P450 oxidoreductase
Miller, W. L., Huang, N., Agrawal, V., & Giacomini, K. M. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.09.017 · Cited by 54
“As n our prior studies of POR mutants (Flück et al., 2004; Huang et 4 h o ata compiled from Huang et al. (2005), Huang et al. (2008) and Agrawal et al. (2008). ata depict Vmax/Km as a percent of the wild-type control, arbitrarily set at 100%.”
BackgroundMethodSelf-citationGenetic susceptibility to caffeine intake and metabolism: a systematic review
Low, J. J.-L., Tan, B. J., Yi, L., Zhou, Z., & Tan, E. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05737-z · Cited by 76
The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency
Gomes, L. G., Huang, N., Agrawal, V., Mendonça, B. B., Bachega, T. A. S. S., & Miller, W. L. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0304 · Cited by 52
Self-citationThe post-translational regulation of 17,20 lyase activity
Miller, W. L., & Tee, M. K. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.09.010 · Cited by 56
Self-citationClinical and Biochemical Consequences of P450 Oxidoreductase Deficiency
Flück, C. E., & Pandey, A. V. (2011) · Endocrine Development · doi:10.1159/000321221 · Cited by 52
Kuypers, D. R. J., de Loor, H., Naesens, M., Coopmans, T., & de Jonge, H. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000095 · Cited by 53
Marohnic, C. C., Panda, S. P., McCammon, K. M., Rueff, J., Masters, B. S. S., & Kranendonk, M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.030445 · Cited by 58
Restoration of mutant cytochrome P450 reductase activity by external flavin
Nicolo, C., Flück, C. E., Mullis, P. E., & Pandey, A. V. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.02.024 · Cited by 50
Chen, X., Pan, L. Q., Naranmandura, H., Zeng, S., & Chen, S. Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038495 · Cited by 53
Kaspera, R., Naraharisetti, S. B., Evangelista, E. A., Marciante, K. D., Psaty, B. M., & Totah, R. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.027 · Cited by 46
Subramanian, M., Agrawal, V., Sandee, D., Tam, H. K., Miller, W. L., & Tracy, T. S. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283544062 · Cited by 43
Self-citationElens, L., Nieuweboer, A. J. M., Clarke, S. J., Charles, K. A., de Graan, A. M., Haufroid, V., van Gelder, T., Mathijssen, R. H. J., & van Schaik, R. H. N. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835dc113 · Cited by 46
Udhane, S. S., Parween, S., Kagawa, N., & Pandey, A. V. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00580 · Cited by 38
Yang, G., Fu, Z.-M., Chen, X., Yuan, H., Yang, H., Huang, Y., Ouyang, D., Tan, Z.-R., Tan, H., Huang, Z., et al. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.004 · Cited by 45
Flück, C. E., Mallet, D., Hofer, G., Samara‐Boustani, D., Léger, J., Polak, M., Morel, Y., & Pandey, A. V. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.08.001 · Cited by 43
Impact on CYP19A1 activity by mutations in NADPH cytochrome P450 oxidoreductase
Flück, C. E., & Pandey, A. V. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.031 · Cited by 43
Pandey, A. V., Flück, C. E., & Mullis, P. E. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.08.072 · Cited by 36
Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation
Serafi, I. E., Afsharian, P., Moshfegh, A., Hassan, M., & Terelius, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141979 · Cited by 39
Bai, Y., Li, J., & Wang, X. (2017) · Journal of Ovarian Research · doi:10.1186/s13048-017-0312-9 · Cited by 34
“For example, the R457H mutation in this patient can inactivate the P450 enzymes including CYP1A2, CYP2C19, CYP2D6 and CYP3A4 which are important for drug metabolism [12, 22, 23].”
Gijsen, V. M. G. J., van Schaik, R. H. N., Soldin, O. P., Soldin, S. J., Nulman, I., Koren, G., & de Wildt, S. N. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3182a3f282 · Cited by 37
Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy
Hu, L., Zhuo, W., He, Y., Zhou, H., & Fan, L. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328358d92b · Cited by 40
Cytochrome P450 Oxidoreductase Deficiency
Idkowiak, J., Cragun, D. L., Hopkin, R. J., & Arlt, W. (2009) · University of Washington, Seattle eBooks · Cited by 33
Zeng, G., Wang, L., Shi, L., Li, H., Zhu, M., Luo, J., & Zhang, Z. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02831-1 · Cited by 33
Dobrinas, M., Cornuz, J., Pedrido, L., & Eap, C. B. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834e9e1a · Cited by 32
Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy
Gong, L., Zhang, C., Lv, J., Zhou, H., & Fan, L. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000297 · Cited by 35
Kramlinger, V. M., Rojas, M. A., Kanamori, T., & Guengerich, F. P. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.665331 · Cited by 31
Nomenclature for alleles of the cytochrome P450 oxidoreductase gene
Sim, S. C., Miller, W. L., Zhong, X.-B., Arlt, W., Ogata, T., Ding, X., Roland Wolf, C., Flück, C. E., Pandey, A. V., Henderson, C. J., et al. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832af5b7 · Cited by 31
Self-citationMoutinho, D., Marohnic, C. C., Panda, S. P., Rueff, J., Masters, B. S. S., & Kranendonk, M. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042820 · Cited by 38
Idkowiak, J., Malunowicz, E. M., Dhir, V., Reisch, N., Szarras-Czapnik, M., Holmes, D. M., Shackleton, C. H. L., Davies, J. D., Hughes, I. A., Krone, N., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0058 · Cited by 30
Modeling of human P450 oxidoreductase structure by in silico mutagenesis and MD simulation
Flück, C. E., Mullis, P. E., & Pandey, A. V. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.09.001 · Cited by 31
History of Adrenal Research: From Ancient Anatomy to Contemporary Molecular Biology
Miller, W. L., & White, P. C. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac019 · Cited by 35
Self-citationHigh-Yield Expression of a Catalytically Active Membrane-Bound Protein: Human P450 Oxidoreductase
Sandee, D., & Miller, W. L. (2011) · Endocrinology · doi:10.1210/en.2011-0230 · Cited by 29
Self-citationMiller, W. L. (2012) · Science Signaling · doi:10.1126/scisignal.2003318 · Cited by 34
Self-citationParween, S., Fernández-Cancio, M., Benito-Sanz, S., Camats, N., Rojas Velazquez, M. N., López-Siguero, J.-P., Udhane, S. S., Kagawa, N., Flück, C. E., Audí, L., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa076 · Cited by 28
Serafi, I. E., & Steele, S. (2024) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2024/4862706 · Cited by 30
Saito, Y., Yamamoto, N., Katori, N., Maekawa, K., Fukushima‐Uesaka, H., Sugimoto, D., Kurose, K., Sai, K., Kaniwa, N., Sawada, J.-I., et al. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-sc-096 · Cited by 27
Neunzig, I., Widjaja, M., Peters, F. T., Maurer, H. H., Hehn, A., Bourgaud, F., & Bureik, M. (2013) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-013-0303-2 · Cited by 32
Velazquez, M. N. R., Parween, S., Udhane, S. S., & Pandey, A. V. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.05.127 · Cited by 31
Parween, S., Velazquez, M. N. R., Udhane, S. S., Kagawa, N., & Pandey, A. V. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01187 · Cited by 24
Cheng, Y., Wang, G., Zhang, W., Fan, L., Chen, Y., & Zhou, H. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1364-9 · Cited by 25
Steroidogenic electron-transfer factors and their diseases
Miller, W. L. (2021) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2142154.077 · Cited by 24
Self-citationSong, T., Wang, B., Chen, H., Zhu, J., & Sun, H. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1393663 · Cited by 24
Guo, C., Pei, Q., Tan, H., Huang, Z., Yuan, H., & Yang, G. (2014) · Biomedical Reports · doi:10.3892/br.2014.395 · Cited by 23
Burris‐Hiday, S. D., & Scott, E. E. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105112 · Cited by 22
Marohnic, C. C., Huber, W. J., Connick, J. P., Reed, J. R., McCammon, K. M., Panda, S. P., Martasek, P., Backes, W. L., & Masters, B. S. S. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.06.008 · Cited by 27
Functional POR A503V is associated with the risk of bladder cancer in a Chinese population
Xiao, X., Ma, G., Li, S., Wang, M., Liu, N., Ma, L., Zhang, Z., Chu, H., Zhang, Z., & Wang, S. (2015) · Scientific Reports · doi:10.1038/srep11751 · Cited by 23
Gu, S., Luo, Q., Wen, C., Zhang, Y. X., Liu, L.-Z., Liu, L., Su, L., Chen, C., Lei, Q., & Zeng, S. Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092289 · Cited by 24
Liu, S., Chen, R., Li, J., Zhang, Y., Wang, X.-D., Fu, Q., Chen, L., Liu, X., Huang, H.-B., Huang, M., et al. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.77 · Cited by 20
Lee, D. H., Lee, H., Yoon, H.-Y., Yee, J., & Gwak, H. S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020261 · Cited by 20
Pharmacogenetics in Jewish populations
Yang, Y., Peter, I., & Scott, S. A. (2014) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2013-0069 · Cited by 18
Drogari, E., Ragia, G., Mollaki, V., Elens, L., van Schaik, R. H., & Manolopoulos, V. G. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.138 · Cited by 19
Pharmaceutical removal from wastewater by introducing cytochrome P450s into microalgae
Kariyawasam, T., Helvig, C. F., Petkovich, M. P., & Vriens, B. (2024) · Microbial Biotechnology · doi:10.1111/1751-7915.14515 · Cited by 23
Tomková, M., Marohnic, C. C., Gurwitz, D., Šeda, O., Masters, B. S. S., & Martásek, P. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.21 · Cited by 17
Fang, Y., Gao, N., Tian, X., Zhou, J., Zhang, H., Gao, J., He, X.-P., Wen, Q., Jia, L.-J., Jin, H., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000490934 · Cited by 19
Tan, S., Li, Z., Zhang, W., Song, G.-B., Liu, L.-M., Peng, J., Liu, Z., Fan, L., Meng, X.-G., Wang, L., et al. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1544-2 · Cited by 16
Almeida-Paulo, G. N., García, I. D., Lubomirov, R., Borobia, A. M., Alonso-Sanchez, N. L., Espinosa, L., & Carcas, A. J. (2017) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.93 · Cited by 14
Hao, C., Guo, J., Guo, R., Qi, Z., Li, W., & Ni, X. (2018) · Pediatric Investigation · doi:10.1002/ped4.12035 · Cited by 13
“For example, the R457H mutation in this patient can inactivate the P450 enzymes including CYP1A2, CYP2C19, CYP2D6 and CYP3A4, which are important for drug metabolism.(15,16) Thus, there may be possible risks if the patients with R457H mutations are treated with medications metabolized by these enzymes.”
BackgroundHuang, K., Liao, X., Han, C., Wang, X., Yu, T., Yang, C., Liu, X., Yu, L., Chen, Z., Qin, W., et al. (2019) · Journal of Cancer · doi:10.7150/jca.28919 · Cited by 13
Goh, J. J. N., Behn, J., Chong, C., Zhong, G., Maurer‐Stroh, S., Fan, H., & Loo, L. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03111-2 · Cited by 14
Strohmaier, S. J., Huang, W., Baek, J., Hunter, D. J. B., & Gillam, E. M. J. (2019) · FEBS Journal · doi:10.1111/febs.14982 · Cited by 15
Rojas Velazquez, M. N., Noebauer, M., & Pandey, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710141 · Cited by 11
“Considering all available data from previous reports [4,46,47] and multiple functional assays described in this manuscript, we suggest that rs17853284, the variant causing amino acid change P228L in POR, is a disease-causing variant, whose effect will be prominent when present together with another variant of POR on t…”
Kumar, R., Jayaraman, M., Ramadas, K., & Chandrasekaran, A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2211674 · Cited by 16
Han, J., Yee, J., Chung, J. E., Lee, K. E., Park, K., & Gwak, H. S. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1201 · Cited by 10
P450 Oxidoreductase Deficiency (PORD)
Flück, C. E., & Pandey, A. V. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416006-4.00010-7 · Cited by 11
Pharmacogenomics aspect of immunosuppressant therapy
Langman, L. J., van Gelder, T., & van Schaik, R. H. N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800885-0.00005-9 · Cited by 14
Human P450 Oxidoreductase Deficiency
Flück, C. E., & Pandey, A. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64966-8 · Cited by 12
Öz, M. D., Özdemir, F., Tok, K. C., Dural, E., Kır, Y., Ulusoy, M., Gümüştaş, M., Başkak, B., & Suzen, H. S. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2221849 · Cited by 6
Hussaini, S. A., Waziri, B., Dickens, C., & Duarte, R. A. B. (2024) · Pharmacogenomics · doi:10.1080/14622416.2024.2370761 · Cited by 8
Jin, Y., Chen, M., Penning, T. M., & Miller, W. L. (2015) · Biochemical Journal · doi:10.1042/bj20141410 · Cited by 6
Self-citationCalculation of CYP450 protein–ligand binding and dissociation free energy paths
Su, K., Wu, C.-T., Lin, S., Mori, S., Liu, W.-M., & Yang, M. (2021) · The Journal of Chemical Physics · doi:10.1063/5.0046169 · Cited by 6
Flück, C. E. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8002-1_1 · Cited by 5
Everton, J. B. F., Patrício, F. J. B., Faria, M. D. S., Ferreira, T. C. A., Filho, N. S., Silva, G. E. B., Romão, E. A., & Magalhães, M. (2022) · Current Drug Metabolism · doi:10.2174/1389200223666220516094226 · Cited by 5
Nakagawa, J., Kinjo, T., Aiuchi, N., Ueno, K., Tomita, H., & Niioka, T. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03424-w · Cited by 5
Genetic Variations in NADPH-CYP450 Oxidoreductase in a Czech Slavic Cohort
Tomková, M., Panda, S. P., Šeda, O., Baxová, A., Hůlková, M., Masters, B. S. S., & Pavel Martasek, E. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.169 · Cited by 6
The Principles, Enzymes, and Pathways of Human Steroidogenesis
Auchus, R. J., & Miller, W. L. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00096-4 · Cited by 6
Self-citationAgrawal, V., & Miller, W. L. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-321-3_19 · Cited by 4
Self-citationÖzdemir, F., Öz, M. D., & Suzen, H. S. (2019) · Current Drug Metabolism · doi:10.2174/1389200220666190913121052 · Cited by 3
Nakagawa, J., Kinjo, T., Aiuchi, N., Ueno, K., Tomita, H., & Niioka, T. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03483-7 · Cited by 3
Metadata
- Authors
- Agrawal, V., Huang, N., & Miller, W. L.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Miller, Walter L.
- Venue
- Pharmacogenetics and Genomics
- Published
- 2008-07
- Volume
- 18
- Issue
- 7
- Pages
- 569-576
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2077782498
- Semantic Scholar
- af016df9ce2ad1c6926bb06668a0312717109fc4
- Cited by
- 117
- References
- 52
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 3 · 2020: 3 · 2019: 6 · 2018: 5 · 2017: 6 · 2016: 4 · 2015: 8 · 2014: 8 · 2013: 9 · 2012: 9
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacogenetics and Genomics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of General Medical Sciences (R01GM073020)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Physical Sciences › Chemistry › Inorganic Chemistry › Metal-Catalyzed Oxygenation Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- cytochrome P450 oxidoreductase, CYP1A2, CYP2C19, drug metabolism
- MeSH terms
- Animals, Aryl Hydrocarbon Hydroxylases, Catalysis, Cell Membrane, Enzyme Activation, Escherichia coli, Humans, Kinetics, Inactivation, Metabolic, Models, Biological, NADPH-Ferrihemoprotein Reductase, Pharmacogenetics, Substrate Specificity, Transformation, Bacterial, Cytochrome P-450 CYP1A2, Polymorphism, Single Nucleotide, Mutant Proteins, Rats, Cytochrome P-450 CYP2C19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.